Clinical trial
The Role of Ampligen in Strategic Therapeutic Intervention (STI) of HAART
NCT00035893 · AIM ImmunoTech Inc., Industry · Completed
Key facts
| NCT number | NCT00035893 |
|---|---|
| Title | The Role of Ampligen in Strategic Therapeutic Intervention (STI) of HAART |
| Official title | The Role of Ampligen in Strategic Therapeutic Intervention (STI) of Highly Active Anti-Retroviral Therapy (HAART): A Multi-Center, Randomized, Controlled Study of Ampligen Potentiation of the HAART-Free Interval. |
| Lead sponsor | AIM ImmunoTech Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HIV Seropositivity, HIV Infection |
| Intervention type | Drug |
| Interventions | poly I-poly C12U |
| Enrollment | 40 |
| Start date | May 1, 2001 |
| Primary completion | Aug 1, 2006 |
| Completion | Aug 1, 2006 |
| First posted | May 7, 2002 |
| Last update posted | Apr 17, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: